ReviewPharmacoepidemiology and drug safety2016
Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines.
Review in Pharmacoepidemiology and drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.Drugs - real world outcomes · 2026Article
- AS01Drug safety · 2026Article
- Background incidence rates and observed-to-expected ratios of adverse events of special interest after covid-19 mRNA vaccination during pregnancy in France: a nationwide population-based study.The Lancet regional health. Europe · 2026Article
- RSV Vaccination Programme for Older Adults: A Scotland-Wide Study on RSVpreF Vaccine Safety.Vaccines · 2025Article
- Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management.Pharmacoepidemiology and drug safety · 2025Review
- Sedative co-medication patterns across frailty states in people with HIV: a network-based study.International journal of clinical pharmacy · 2025Article
- Article
- Challenges and Innovations in Pharmacovigilance and Signal Management During the COVID-19 Pandemic: An Industry Perspective.Vaccines · 2025Review
- Evaluating the Accuracy of Responses by Large Language Models for Information on Disease Epidemiology.Pharmacoepidemiology and drug safety · 2025Article
- How do large-scale population studies inform vaccine evaluations in England?Clinical and experimental immunology · 2025Review
- The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective.Frontiers in drug safety and regulation · 2025Review
- Background incidence rates from electronic healthcare databases for vaccine safety monitoring: review of challenges from the COVID-19 vaccination campaign and proposal for best practices.Frontiers in drug safety and regulation · 2025Article
- Observational
- Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.Drug safety · 2024Article
- The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.Drug safety · 2024Article
- Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273.Open forum infectious diseases · 2024Article
- Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.Drug safety · 2023Article
- Comment on "Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project".Drug safety · 2023Article
- Challenges in Assessing COVID-19 Vaccines Safety Signals-The Case of ChAdOx1 nCoV-19 Vaccine and Corneal Graft Rejection.Vaccines · 2023Article
- A Pharmacoepidemiological Study of Myocarditis and Pericarditis Following the First Dose of mRNA COVID-19 Vaccine in Europe.Microorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.